Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The Egyptian Ministry of Antiquities is pleased to announce the launch of an egyptian – international Project using non-invasive and non-destructive surveying techniques for the scanning of Egyptian Pyramids under the title “ScanPyramids” project.
Just because a mystery is 4500 years old doesn’t mean it can’t be solved…” This could be the motto of the exceptional scientific mission launched October 25, 2015, under the authority of the Egyptian Ministry of Antiquities, initiated, designed and coordinated by the Faculty of Engineering of Cairo and the French HIP.Institute (Heritage, Innovation and Preservation). Radiographic muons, aka cosmic particles, infrared thermography, photogrammetry, scanner and 3D reconstruction: the most innovative technologies will be used by researchers of international renown and three major universities: the Faculty of Engineering of Cairo University, Université Laval of Quebec and Nagoya University of Japan. Their goal: to probe the heart of the largest pyramids of Egypt, without drilling the slightest opening.
Four millennia after their construction, these ancient giants are far from having yielded their secrets. The first mystery concerns their construction, especially Khufu, the last of the Seven Wonders of the Ancient World still existing: it is still impossible to describe with certainty how this stone monument, the largest ever built by humans, was erected.
The “ScanPyramids” project has already been approved by the permanent committee of the Ministry of Antiquities and has obtained all necessary permissions from concerned authorities. With a base of more than 5 hectares, its original height of almost 150 meters and a mass of 5 million tons, how was it possible to construct such a wonder in only 25 years?
To view the multimedia release go to:
http://www.multivu.com/players/uk/7671551-scanpyramids-project-launch-egyptian/
The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience includes an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program’s alignment with the United States’ Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is expected to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
“We are very excited to extend our commitment to the Amgen Biotech Experience, a program that began 25 years ago, with the intent to ignite a deep passion for innovation and scientific discovery in students,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “This program, which provides advanced biotech curriculum and professional-grade lab equipment at no cost to schools, has opened countless students’ eyes to the world of biotechnology, fueling potential long term advancements to both medicine and society.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7414055-amgen-biotech-experience-grant/
Subaru of America, Inc. today announced the completion of a Pet Travel Seat Pilot Study as part of its continued partnership with Center for Pet Safety (CPS), a registered 501(c)(3) non-profit research and consumer advocacy organization. Subaru and CPS have tested pet products most commonly used by pet parents when traveling. Phase one tested pet harnesses, phase two tested pet crates and carriers, and now, phase three has tested pet travel seats.
A pet travel seat is typically used in a vehicle to hold or elevate the pet, but does not offer full containment. The Pet Travel Seat Pilot Study found that while a pet travel seat may offer distraction prevention, it will likely not offer crash protection in the event of an accident, which could lead to injury of the pet and the human vehicle passengers. The quality of commonly available pet travel seats did not provide effective protection in a crash scenario.
Based on the scientific test evidence collected over the past four years, in part through its partnership with Subaru, CPS can now identify the safest travel options for most pets. For small dogs and cats, Center for Pet Safety recommends one of the 2015 Top Performing Carriers; for medium and large dogs either the 2015 Top Performing Crate - Gunner Kennels G1 Intermediate with 8' Tie Down Straps, or a Center for Pet Safety Certified Harness. To view top performing products and CPS Certified products, visit www.CenterforPetSafety.org.
To view the multimedia release go to:
http://www.multivu.com/players/English/7074158-subaru-cps-pet-travel-seat-study/
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today congratulated trusted Edwards partner Dr. Albert Starr on receiving the 2015 Institut de France’s Grand Prix Scientifique in a Paris awards ceremony.
The Grand Prix is one of the largest prizes for scientific accomplishment and is considered the world’s most prestigious prize for cardiovascular research. The Institut’s board awarded Starr the Grand Prix in recognition of research that led to the world’s first successful artificial mitral valve implant in 1960. In the last 55 years, millions of patients around the world have benefitted from the emergence of the field of heart valve replacement and the many technological advances that followed.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7536851-france-grand-prix-starr-edwards/
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
A recently published scientific study from Lund University by lead researcher Charlotte Erlanson-Albertsson, MD, PhD found that subjects who were trying to lose weight and used the patented spinach extract Appethyl on a daily basis lost 43 percent more weight compared to those ingesting a placebo.
In this clinical trial, overweight women were given either a daily five gram dose of Appethyl or a control drink immediately before breakfast. Researchers found that the weight of the women ingesting Appethyl decreased significantly at 43 percent more than subjects ingesting the control drink.
This is one of three studies that also compared the effects of Appethyl after 90 days with those found after the first dose and found no decline of effects, indicating that Appethyl takes effect after the first dose and is just as effective after long-term use. One study showed that Appethyl reduced hunger by 25 percent four hours after consumption, in addition to reducing thoughts about food by 33 percent.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7426951-appethyl-spinach-extract/
The Crohn’s & Colitis Foundation of America (CCFA) is collaborating with the University of North Carolina School of Medicine (UNC) to create a research partnership between patients with inflammatory bowel disease (IBD) and the scientific community. CCFA Partners is a “patient-powered research network” for Crohn’s disease and ulcerative colitis (collectively known as IBD) that uses state-of-the-art bioinformatics to engage and gather information from patients that researchers can study and analyze along with clinical and other patient-generated data.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7449851-crohn-s-colitis-foundation-ccfa-ibd/
Casino operators at the ICE Totally Gaming 2015 conference and trade show (“ICE 2015”) will experience first-hand the strategic benefits of the combination of Scientific Games’ (NASDAQ: SGMS) Bally, WMS, Shuffle Master, SG Gaming, Williams and Barcrest brands. At ICE 2015 on February 3-5 at ExCel London Exhibition and Convention Center, stand #N1-440, Scientific Games (the “Company”) will showcase more than 125 gaming products that address casino operators’ diverse needs across all of their land-based and interactive channels, thereby demonstrating the value of the Company’s recent merger with Bally Technologies. For more details on Scientific Games’ products on display at ICE 2015, please visit now.wms.com/stronger-together-ice2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7405051-scientific-games-ice-2015/
Barrister, peer and Vice-President of the Patients Association Baroness Helena Kennedy has joined a panel of internationally recognised experts for the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
Organised and funded by Astellas, a progressive pharmaceutical company that explores the frontiers of scientific discovery to translate new knowledge into innovative, reliable medicines, the Astellas Innovation Debates are a series of annual events that bring together some of the world’s most progressive thinkers to discuss the role of innovation in solving some of the greatest challenges of our time.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7424051-helena-kennedy-astellas-debate/
George Freeman MP, the Minister for Life Sciences, will give the keynote address at the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
Organised and funded by Astellas, a progressive pharmaceutical company that explores the frontiers of scientific discovery to translate new knowledge into innovative, reliable medicines, the Astellas Innovation Debates are a series of annual events that bring together some of the world’s most progressive thinkers to discuss the role of innovation in solving some of the greatest challenges of our time.
George Freeman’s keynote address will outline the Government’s aim to develop, assess and adopt new drugs, devices and diagnostics as we move towards 21st century, personalised healthcare.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7423951-george-freeman-astellas-debate/
